AstraZeneca VOLGA Phase III Trial Meets EFS and OS Endpoints
AstraZeneca said perioperative Imfinzi plus neoadjuvant enfortumab vedotin met VOLGA Phase III endpoints in MIBC. The trial cut EFS risk by 49% (HR 0.51; p<0.0001) and death risk by 42% (HR 0.58; p=0.0027); median EFS and OS were not yet reached.
AstraZeneca said perioperative IMFINZI plus neoadjuvant enfortumab vedotin met VOLGA Phase III endpoints in MIBC, cutting EFS risk by 49% (HR 0.51; p<0.0001) and death risk by 42% (HR 0.58; p=0.0027), with median EFS and OS not yet reached.Material DetailsContext by AI AnalystThis is a late-stage c…